Drug Search Results
More Filters [+]

Filanesib

Alternative Names: filanesib, arry-520, arry520, arry 520
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: KIF Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Filanesib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Myeloma

Phase 2: Multiple Myeloma|Leukemia, Plasma Cell|Myelodysplastic Syndrome|Acute Myeloid Leukemia

Phase 1: Multiple Myeloma|Leukemia, Plasma Cell|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

POMDEFIL

P2

Terminated

Multiple Myeloma

2020-03-23

NCI-2011-01120

P1

Completed

Multiple Myeloma|Leukemia, Plasma Cell

2019-05-16

POMDEFIL

P2

Completed

Multiple Myeloma

2018-02-01

Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

P2

Completed

Multiple Myeloma

2017-09-12

Recent News Events